Milton Keynes Formulary
We acknowledge receipt and implementation of Technology Appraisals issued by NICE. Where there is a recommendation for a drug to be made available or as an option, we fully comply with NICE guidance. See NICE Adherence Checklist.
The Joint Formulary is produced as a joint venture between primary and secondary care. It has been designed as a tool to assist in promoting safe, cost-effective prescribing within the Milton Keynes Area. The aim is that the Joint Formulary will cover 80-90% of prescribing within the Milton Keynes Health Community although we recognise that there will be instances where prescribing outside of the formulary will be both necessary and appropriate.
It is prepared by the Milton Keynes Prescribing Advisory Group (MKPAG) in consultation with consultant specialists, GP’s, primary and secondary care prescribers, pharmacists and with others who have a particular interest and/or knowledge in specific areas of therapeutics whilst also taking into account Patient factors, Clinical efficacy, Safety, Cost effectiveness, Clinician choice/experience, National guidelines e.g. NICE guidelines
Use of the Joint Formulary will also help to ensure seamless prescribing for patients between Primary and Secondary Care, thereby reducing the confusion and possible errors that can happen when medications are changed. The formulary is continually evolving and its contents are kept under constant review.
Drug expenditure and use of FP10(HP) forms
It should be noted that items prescribed on FP10 (HP) forms and dispensed in a community pharmacy are charged to the Trust. Therefore the rules with regard to Trust formulary prescribing and length of treatment must be followed. Prescriptions should be issued from out-patient clinics only when drug treatment is required to start immediately. In all other circumstances treatment recommendations should be communicated to the patient\'s GP using the out-patient clinic communication form. Patients should be encouraged to keep up to date with their usual medication supplies and informed that these may not be supplied from out-patient clinics.
A breakdown of drug expenditure (including FP10 expenditure) is reported quarterly to each Business Unit. Non-formulary and other inappropriate prescribing will be identified and reported to the Business Unit leads.